Please assess the completion status of the following clinical trial:

Trial Title: S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed renal cell carcinoma~  * Metastatic (M1) disease OR~ * M0 provided the primary tumor is unresectable~* Measurable disease~  * At least 1 unidimensionally measurable lesion~ * Soft tissue disease that has been irradiated within the past 2 months is not considered measurable disease~ * Soft tissue disease within a prior radiation field is measurable provided it has progressed since therapy and there is also measurable disease outside of the irradiated field~* No prior or concurrent brain metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (SGOT) no greater than 1.5 times ULN~Renal~* Creatinine clearance at least 50 mL/min~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other concurrent uncontrolled illness that would preclude study participation~* No psychiatric illness or social situation that would preclude study compliance~* No uncontrolled diabetes mellitus~* No ongoing or active infection~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No more than 2 prior immunotherapy regimens comprising interferon (IFN) and/or interleukin-2 (IL-2)~* At least 28 days since prior IFN or IL-2 and recovered~Chemotherapy~* No prior chemotherapy for renal cell cancer~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* No prior radiotherapy to 25% or more of the bone marrow~* At least 21 days since prior radiotherapy and recovered~Surgery~* At least 28 days since prior surgery and recovered~* Prior resection of the primary tumor allowed (in patients with metastatic disease)~Other~* At least 4 weeks since prior sorivudine or brivudine~* No concurrent sorivudine or chemically related analogues (e.g., brivudine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Gemcitabine + Capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).